Hemab discloses material control weaknesses in debut 10-Q; $317M IPO extends runway to 2029

Filed May 21, 2026 · Period ending March 31, 2026 · ~2 min read

Key Changes

• high

  Company identified material weaknesses in financial close process and IT controls during 2024-2025 audits, meaning reasonable possibility that material misstatements won't be detected timely. Remediation underway with external advisors and new hires.

  Controls & Procedures verify on EDGAR →
• high

  IPO closed May 2026 with $317M net proceeds; combined with $164M cash on hand, management projects runway into 2029. Q1 2026 net loss $22.7M vs $15.3M prior year, accumulated deficit $205M.

  MD&A: Liquidity verify on EDGAR →
• high

  Two clinical-stage assets represent entire pipeline: sutacimig (Phase 1/2 for Glanzmann thrombasthenia, Phase 2 for Factor VII deficiency) and HMB-002 (Phase 1/2 for Von Willebrand Disease). Planned Phase 3 trial for sutacimig will be substantially more expensive.

  MD&A: Clinical Programs verify on EDGAR →